Zevra Therapeutics (ZVRA) director Bode bought 10,000 shares for $79.6K at $7.96
Stocks in this Quantisnow insightHealth Care
Insider transactions reported
John B Bode (director at Zevra Therapeutics Inc., ZVRA) reported that they bought 10,000 shares for $79.6K at $7.96 on Mar 19, 2025. After these transactions the filing shows 40,000 shares held directly.
- Reporting person
- Bode John B
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| Mar 19, 2025 | Open-market purchase (P) | Common Stock1 | +10,000 | $7.96 | $79.6K | 40,000 direct |
Holdings before and after
- Common Stock: 30,000 to 40,000 direct
Footnotes from the filing
- 1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.91 to $8.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Transaction codes in this filing
- Open-market purchase:
- Code P marks a purchase in the open market or a private deal. The insider paid for these securities.
FAQ
What did Bode report in this ZVRA Form 4?
John B Bode (director at Zevra Therapeutics Inc., ZVRA) reported that they bought 10,000 shares for $79.6K at $7.96 on Mar 19, 2025. After these transactions the filing shows 40,000 shares held directly.
How many ZVRA shares does Bode hold after this filing?
The filing shows 40,000 shares held directly after the reported transactions. Form 4 reports only the positions it lists, so this may not be every holding.
What does transaction code P mean on an SEC Form 4?
Code P marks a purchase in the open market or a private deal. The insider paid for these securities.
Historical context for ZVRA
Earlier insider filings at ZVRA
- Feb 14, 2025SVP, Finance & Corp Controller Sangiovanni Timothy J. sold $23,588 worth of shares (3,000 units at $7.86), decreasing direct ownership by 16% to 16,341 units (SEC Form 4)
- Feb 14, 2025CCO & EVP, Bus. Development Schafer Joshua sold $82,527 worth of shares (10,500 units at $7.86), decreasing direct ownership by 26% to 29,486 units (SEC Form 4)
- Feb 14, 2025CFO & Treasurer Clifton R. Laduane sold $86,471 worth of shares (11,000 units at $7.86), decreasing direct ownership by 18% to 51,361 units (SEC Form 4)
- Feb 14, 2025President and CEO Mcfarlane Neil F. sold $727,390 worth of shares (91,817 units at $7.92), decreasing direct ownership by 32% to 191,516 units (SEC Form 4)
- Feb 10, 2025SEC Form 4 filed by President and CEO Mcfarlane Neil F.
Quantisnow market dataNASDAQ
ZVRA
Zevra Therapeutics Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
Get push alerts for ZVRA
Full ZVRA profile on Quantisnow Follow ZVRA and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time